Abstract library

208 results for "socio-economic status".
#1349 Access to Care and Outcomes for Neuroendocrine Tumors: Does Socio-Economic Status Matter? A Population-Based Analysis.
Introduction: Neuroendocrine Tumors (NET) lack standardized care. Differences in socioeconomic status (SES) worsen the impact of non-standardized care.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Hallet Julie
#2098 Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status
Introduction: Malnutrition is a clinical relevant problem in NEN-patients (pts) independently influencing overall prognosis, particularly in pts undergoing chemotherapy (CTx). A poor nutritional status (NS) in pts of all WHO-grades was associated with a significantly shorter long-term outcome
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Sophie Pevny
#2228 Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Non Functioning Pancreatic Neuroendocrine Tumors: Outcome Analysis from 378 Consecutive Resections in a High-Volume Institution
Introduction: The optimal management of regional lymph nodes during resections of Pancreatic Neuroendocrine Tumors (pNETs) remains controversial. Conflicting data exist on predictors of LN metastases (LNM) and their impact on survival
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: doctor Anna Malpaga
Authors: Malpaga A, Miotto M, Elio G, Nessi C, ...
#2178 Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumor: Preliminary Baseline Characteristics from the Nutrition in NETs Study
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP NET) cause various symptoms impacting on nutritional status and diet. Published data indicates up to 25% of GEP NET patients are malnourished, and dietary change is prevalent. Further research is required to guide nutrition recommendations.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Erin Kennedy
Authors: Kennedy E, Kiss N, Michael M, Gough K, ...
#828 Challenging in Predicting Response in Treatment of Neuroendocrine Pancreatic Tumors: Nutritional Factors
Introduction: Neuroendocrine pancreatic tumors (NEPT) include a heterogeneous neoplasms group in pathophysiology, clinical manifestations, treatment and prognosis.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Cristina Tejera
#3054 Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumour: Nutrition in NETs Study
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP NET) can adversely affect nutritional status. Cross-sectional studies report up to 25% of GEP NET patients are malnourished and dietary change may be prevalent. Nevertheless, clinical guidelines lack advice on nutrition management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Erin Laing
#3072 Rb and p53 Status Determination by Immunochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms
Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Jerome Cros
#1067 Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?
Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Anne-Sophie Dussol
#1190 Blood Gene Transcript Analysis Predicts 68Ga- SSA-PET/CT Imaging in Neuroendocrine Tumors and Defines Disease Status
Introduction: Limitations of biomarkers and imaging are a concern in the identification of NET status and therapy response.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Kidd M, Modlin I, Drozdov I, ...
#2872 Characteristics of the Immunophenotype and the Status of Receptors for Somatostatin Type 2 and 5 of Typical and Atypical Carcinoids of the Lung
Introduction: Carcinoids of the lung are a wide range of tumors with various malignancy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Larisa Gurevich